Graphene Oxide/Silver Nanoparticle Coating Produced by Electrophoretic Deposition Improved the Mechanical and Tribological Properties of NiTi Alloy for Biomedical Applications.

The aim of this study was to evaluate the mechanical and tribological properties of graphene oxide/silver nanoparticle (GO/AgNP) coated medical grade nickel-titanium (NiTi) alloy. The alloy substrates were coated using electrophoretic deposition at 30 V for 1, 5, and 10 min and were characterized by SEM, Raman spectroscopy, EDS, and surface profilometer. Mechanical and tribological tests were performed for hardness, Young's modulus, and friction coefficient. The data were analyzed using the Kruskal-Wallis test at a significance level of 0.05 to compare the coatings' roughness, thickness, friction coefficient, and hardness at the different coating times. The GO/AgNP coatings were confirmed with Raman spectroscopy, which demonstrated the presence of D bands and G bands at ∼1300 cm-1 and ∼1600 cm-1. The intensity ratios of the D and G bands (ID/IG) were 0.838, 0.836, and 0.837 in the 1, 5, and 10 min coated groups, respectively. The coating thickness ranged from 0.46-1.34 µm and the mean surface roughness (Ra) ranged from 50.72-69.93 nm. Increasing the coating time from 1-10 min increased the roughness, thickness, and Young's modulus of surface coating. The friction coefficients of the coated NiTi alloy were significantly lower compared with that of the uncoated NiTi allloy (p < 0.001). The GO/AgNP nanocomposite coated NiTi alloy demonstrated improved mechanical strength and a reduced friction coefficient that would be more favorable for biomedical applications.

Polymeric materials and films in dentistry: An overview.

The use of polymeric materials (PMs) and polymeric films (PMFs) has increased in medicine and dentistry. This increasing interest is attributed to not only the excellent surfaces of PMs and PMFs but also their desired mechanical and biological properties, low production cost, and ease in processing, allowing them to be tailored for a wide range of applications. Specifically, PMs and PMFs are used in dentistry for their antimicrobial, drug delivery properties; in preventive, restorative and regenerative therapies; and for corrosion and friction reduction. PMFs such as acrylic acid copolymers are used as a dental adhesive; polylactic acids are used for dental pulp and dentin regeneration, and bioactive polymers are used as advanced drug delivery systems. The objective of this article was to review the literatures on the latest advancements in the use of PMs and PMFs in medicine and dentistry. Published literature (1990-2017) on PMs and PMFs for use in medicine and dentistry was reviewed using MEDLINE/PubMed and ScienceDirect resources. Furthermore, this review also explores the diversity of latest PMs and PMFs that have been utilized in dental applications, and analyzes the benefits and limitations of PMs and PMFs. Most of the PMs and PMFs have shown to improve the biomechanical properties of dental materials, but in future, more clinical studies are needed to create better treatment guidelines for patients.

Mucoadhesive drug carrier based on functional-modified cellulose as poorly water-soluble drug delivery system.

The purpose of this study was to design and characterise an oral mucoadhesive micellar drug carrier. In this regard, a mucoadhesive hydrophobic cationic aminocellulose was easily synthesised under mild homogeneous conditions with high yield. The cellulose derivative resulted in strongly improved mucoadhesive properties but was pH dependent. Furthermore, the hydrophobic anticancer drug camptothecin was successfully encapsulated into the mucoadhesive cellulose derivative micelles with spherical shape stability of 233 nm in diameter and low particle size distribution. The CPT-loaded nanocarriers provided high encapsulation efficiency about 86.4%. In vitro release, CPT-loaded cellulose derivative micelles showed a reduction in release rate compared with physically pure CPT solution. The release results also indicated that a sustained release of CPT to >80% over 4 d for pH 6.8 and 7.4. Therefore, mucoadhesive hydrophobic cationic aminocellulose micelles seem to be a promising carrier for various pharmaceutical applications especially for poorly water-soluble drug delivery system.

Enhanced water-solubility and mucoadhesion of N,N,N-trimethyl-N-gluconate-N-homocysteine thiolactone chitosan.

A water-soluble chitosan with improved mucoadhesion was prepared by modifying 19.4% of the amine groups of chitosan to trimethylammonium and conjugation of gluconolactone (GLU) and homocysteine thiolactone (HT) onto the remaining amine groups of the chitosan backbone. The derived trimethyl-gluconate-HT-chitosan (TM-GN-HT-chitosan) was confirmed by Fourier Transform Infrared spectroscopy, NMR and thermogravimetric analysis. The total thiol and disulfide group level on the TM-GN-HT-chitosan were 17.96 ± 0.03 and 7.36 ± 0.03 µmol/g, respectively. The water solubility of the TM-GN-HT-chitosan conjugate was 79.0 ± 0.15%, more than that of TM-chitosan and chitosan, with an enhanced solubility over a broad pH range ranging from 85.6 ± 10.4% to 58.5±1.1% maximal solubility at pH 2 to 11. Finally, TM-GN-HT-chitosan showed a nearly ∼9.5-, 5.0- and 5.6-fold higher mucoadhesiveness than chitosan at pH 1.2, 4.0 and 6.4, respectively, and was optimal at pH 4.0.

Enhanced anti-topoisomerase II activity by mucoadhesive 4-CBS-chitosan/poly (lactic acid) nanoparticles.

In this study, the biodegradable mucoadhesive 4-carboxybenzensulfonamide chitosan (4-CBS-chitosan)/poly (lactic acid) (PLA) nanoparticles were fabricated by the electrospray ionization technique for enhancing anti-topoisomerase II (Topo II) activity. The obtained (4-CBS-chitosan/PLA)-DOX nanoparticles were characterized using SEM, particle size analyzer. We emphasis on encapsulation efficiency, in vitro drug release behavior and also performed in vitro studies of Topo II inhibitory activity using gel electrophoresis. In addition, the cytotoxicity of the 4-CBS-chitosan/PLA nanoparticles using MTT assay was also studied. The mean particle size of spherical shaped (4-CBS-chitosan/PLA)-DOX is less than 300 nm. The DOX loaded 4-CBS-chitosan/PLA composite nanoparticles produced high entrapment efficiency of 85.8% and provided the prolonged release of DOX extended to 26 days and also still had strong Topo II inhibitory activity up to 77.4%. Overall, it was shown that 4-CBS-chitosan/PLA nanoparticles could be promising carriers for controlled delivery of anticancer drugs.

Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin.

This work focused on a new technique for the preparation of doxorubicin (DOX) loaded chitosan (CS) nanoparticles (DOX-CS) - formation by electrospray ionization in the presence of tripolyphosphate (TPP) as the stabilizer. The working distance, needle gauge, flow rate, stirring rate, electrospraying voltage and DOX to CS molar ratio were sequentially and individually optimized and found to be a 26 gauge needle, an applied voltage of 13 kV, a flow rate of 0.5 mL/h, a working distance of 8 cm and a stirring rate of 400 rpm. The incorporation of chemically unchanged DOX with the CS into the particles was ascertained by Fourier transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Under these optimized conditions, the DOX-CS particles were found to be nanoparticles of approximately 300-570 (dry particles) or 530-870 nm diameter (hydrated particles), with a PDI and SPAN polydispersity indices of 0.97-0.82 and 0.62-0.64, respectively, for initial DOX loading levels of 0.25-1%, as determined by SEM and particle size analyzer, respectively. Moreover, a high encapsulation efficiency (EE) of DOX into the nanoparticles was attained, ranging from 63.4 to 67.9% EE at 1 to 0.25% DOX loading. Finally, the in vitro DOX release behaviors of the DOX-CS particles revealed a prolonged release of DOX over at least seven hours.